<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Bendamustine and rituximab for non-Hodgkin lymphoma&lt;sup&gt;[1,2]&lt;/sup&gt;</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Bendamustine and rituximab for non-Hodgkin lymphoma<sup>[1,2]</sup></h1>
<div class="graphic"><div class="figure"><div class="ttl">Bendamustine and rituximab for non-Hodgkin lymphoma<sup>[1,2]</sup></div><div class="cntnt"><table cellspacing="0"><colgroup span="2" width="20%"></colgroup><colgroup width="40%"></colgroup><colgroup width="20%"></colgroup> <tbody> <tr class="divider_bottom"> <td colspan="4"><strong>Cycle length:</strong> 28 days. </td> </tr> <tr class="divider_top"> <td class="subtitle1 divider_bottom">Drug</td> <td class="subtitle1 divider_bottom">Dose and route</td> <td class="subtitle1 divider_bottom">Administration</td> <td class="subtitle1 divider_bottom">Given on days</td> </tr> <tr> <td>Rituximab</td> <td>375 mg/m<sup>2</sup> IV</td> <td>Dilute in normal saline (NS) or 5% dextrose in water to a final concentration of 1 to 4 mg/mL. Initial infusion: Start at 50 mg/hour; escalate in 50 mg/hour increments every 30 minutes to a maximum of 400 mg/hour, as tolerated. In the absence of an initial infusion reaction, patients without clinically significant cardiovascular disease may receive subsequent infusions over 90 minutes.* For the 90-minute infusion, administer 20% of the total dose over the first 30 minutes and the remaining 80% over 60 minutes, as tolerated.<sup>¶</sup><sup>[3]</sup></td> <td>Day 1</td> </tr> <tr class="divider_bottom"> <td>Bendamustine</td> <td>90 mg/m<sup>2</sup> IV<sup>Δ</sup></td> <td>Dilute<sup>◊</sup> in 500 mL NS or 2.5% dextrose/0.45% sodium chloride to a final concentration of 0.2 to 0.6 mg/mL.<sup>§</sup> Administer over 60 minutes.</td> <td>Days 1 and 2</td> </tr> <tr class="divider_top"> <td class="subtitle1_left" colspan="4">Pretreatment considerations:</td> </tr> <tr> <td class="indent1"><strong>Emesis risk</strong></td> <td colspan="3"> <ul> <li>MODERATE.</li> <li>Refer to UpToDate topics on prevention of chemotherapy-induced nausea and vomiting in adults.</li> </ul> </td> </tr> <tr> <td class="indent1"><strong>Prophylaxis for infusion reactions</strong></td> <td colspan="3"> <ul> <li>Premedicate with acetaminophen and diphenhydramine, with or without an H2 receptor blocker, 30 minutes prior to at least the first and second infusions of rituximab.<sup>[4]</sup> There is no standard premedication for the initial bendamustine dose. Consider premedication with antihistamines, antipyretics, and corticosteroids for patients with a previous grade 1 or 2 infusion reaction to bendamustine.<sup>[5-7]</sup></li> <li>Refer to UpToDate topics on infusion reactions to therapeutic monoclonal antibodies used for cancer therapy.</li> </ul> </td> </tr> <tr> <td class="indent1"><strong>Vesicant/irritant properties</strong></td> <td colspan="3"> <ul> <li>Bendamustine is an irritant with vesicant-like properties; ensure proper needle or catheter placement prior to and during infusion. Avoid extravasation (particularly by avoiding use of closed system transfer devices, adapters, and syringes containing polycarbonate or acrylonitrile-butadiene-styrene [ABS] with Treanda injection solution<sup>◊</sup>); monitor IV site for redness, swelling, or pain.</li> <li>Refer to UpToDate topics on extravasation injury from chemotherapy and other non-antineoplastic vesicants.</li> </ul> </td> </tr> <tr> <td class="indent1"><strong>Infection prophylaxis</strong></td> <td colspan="3"> <ul> <li>The specific incidence of febrile neutropenia was not reported, however, the incidence of grade 3 or 4 neutropenia was 29 to 49% and the incidence of grade 3 or 4 infection was 7 to 12%.<sup>[1,2]</sup> Primary prophylaxis with hematopoietic growth factors should be considered on an individual basis. Antiviral prophylaxis and <em>Pneumocystis jirovecii</em> prophylaxis are also individualized.</li> <li>Refer to UpToDate topics on use of granulocyte colony stimulating factors in adult patients with chemotherapy-induced neutropenia and conditions other than acute leukemia, myelodysplastic syndrome, and hematopoietic cell transplantation.</li> </ul> </td> </tr> <tr> <td class="indent1"><strong>Dose adjustment for baseline liver or renal dysfunction</strong></td> <td colspan="3"> <ul> <li>Treanda should not be used in patients with a creatinine clearance &lt;40 mL/min. Bedenka should not be used in patients with a creatinine clearance &lt;30 mL/min. Bendamustine should be used with caution in patients with mild hepatic and renal impairment. Bendamustine should not be used in patients with moderate to severe (AST or ALT &gt;2.5 times the ULN and total bilirubin &gt;1.5 times the ULN) hepatic impairment.<sup>[5-7]</sup></li> <li>Refer to UpToDate topics on chemotherapy hepatotoxicity and dose modification in patients with liver disease, conventional cytotoxic agents; chemotherapy hepatotoxicity and dose modification in patients with liver disease, molecularly targeted agents; and chemotherapy nephrotoxicity and dose modification in patients with renal insufficiency, conventional cytotoxic agents.</li> </ul> </td> </tr> <tr class="divider_bottom"> <td class="indent1"><strong>Hepatitis screening</strong></td> <td colspan="3"> <ul> <li>Patients should be screened for hepatitis B and C prior to starting rituximab, and if positive, considered for antiviral prophylaxis.</li> <li>Refer to UpToDate topics on hepatitis B virus reactivation associated with immunosuppressive therapy.</li> </ul> </td> </tr> <tr class="divider_top"> <td class="subtitle1_left" colspan="4">Monitoring parameters:</td> </tr> <tr> <td colspan="4"> <ul class="decimal_heading"> <li>Obtain CBC with differential weekly (initially).<sup>[5-7]</sup></li> </ul> </td> </tr> <tr> <td colspan="4"> <ul class="decimal_heading"> <li>Assess electrolytes and liver and renal function prior to each treatment.</li> </ul> </td> </tr> <tr> <td colspan="4"> <ul class="decimal_heading"> <li>Carriers of hepatitis B or C virus should be monitored for clinical and laboratory signs of active infection during and following completion of therapy. Rituximab should be discontinued if reactivation occurs.</li> <li>Refer to UpToDate topics on hepatitis B virus reactivation associated with immunosuppressive therapy.</li> </ul> </td> </tr> <tr class="divider_bottom"> <td colspan="4"> <ul class="decimal_heading"> <li>Monitor IV infusion site for redness, swelling, pain, infection, and necrosis during and after the bendamustine infusion.</li> </ul> </td> </tr> <tr class="divider_top"> <td class="subtitle1_left" colspan="4">Suggested dose modifications for toxicity:</td> </tr> <tr> <td class="indent1"><strong>Myelotoxicity</strong></td> <td colspan="3"> <ul> <li>Delay treatment if absolute neutrophil count &lt;1000/microL, platelet count &lt;75,000/microL, or if there is an active infection.<sup>[4-7]</sup> If grade 4 hematologic toxicity occurs, reduce dose to 60 mg/m<sup>2</sup> on days 1 and 2 of each cycle.<sup>[2,5-7]</sup> Further dose reductions or dose re-escalation may be done at the discretion of the physician.</li> </ul> </td> </tr> <tr class="divider_bottom"> <td class="indent1"><strong>Other toxicity</strong></td> <td colspan="3"> <ul> <li>For grade 3 or greater nonhematologic toxicity, reduce bendamustine dose to 60 mg/m<sup>2</sup> on days 1 and 2 of the treatment cycle.<sup>[5-7]</sup> If toxicity resolves, doses may be cautiously re-escalated on subsequent cycles. Further dose reductions or dose re-escalation may be done at the discretion of the physician.</li> </ul> </td> </tr> <tr class="divider_top"> <td class="highlight_gray_text" colspan="4" style="font-size: 1.2em;"><strong>If there is a change in body weight of at least 10%, doses should be recalculated.</strong></td> </tr> </tbody></table></div><div class="graphic_lgnd"><strong>This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy, who should use independent medical judgment in the context of individual circumstances to make adjustments, as necessary.</strong></div><div class="graphic_footnotes">IV: intravenous; AST: aspartate aminotransferase; ALT: alanine aminotransferase; ULN: upper limit of normal; CBC: complete blood count.<br/>
* In the absence of an initial reaction, an alternative schedule for subsequent rituximab infusions is to start at 100 mg/hour and escalate in 100 mg/hour increments every 30 minutes to a maximum of 400 mg/hour as tolerated.<sup>[4]</sup> If there is an infusion reaction to any dose, follow the initial infusion guidelines described above.<br/>
¶ A subcutaneous formulation (rituximab-hyaluronidase) that uses a fixed dose and a shorter administration time is an acceptable alternative for patients who have tolerated at least one full dose of intravenous rituximab.<sup>[8]</sup> Dosing varies by histology and clinicians should refer to the United States Prescribing Information for details.<br/>
Δ Increased deaths have been reported in older patients (eg, &gt;70 years) treated with bendamustine plus rituximab;<sup>[9]</sup> we modify the treatment plan for these patients by lowering the dose of bendamustine (to 70 mg/m<sup>2</sup>), limiting the number of cycles, or offering an alternative chemotherapy backbone.<br/>
<span class="lozenge">◊</span> Standard bendamustine solution (Treanda injection<sup>[5]</sup>) is not compatible with closed system transfer devices, adapters, and syringes containing polycarbonate or acrylonitrile-butadiene-styrene (ABS), since these plastics can dissolve upon contact.<br/>
§ Concentration and infusion length recommendations for Treanda are for lyophilized powder, which is available as 25 mg/vial or 100 mg/vial.<sup>[6]</sup> If using Treanda injection solution (which is available as a 45 mg/0.5 mL or 180 mg/2 mL solution), the recommended final concentration is 0.2 to 0.7 mg/mL, infused over 60 minutes.<sup>[5]</sup> If using Bendeka 25 mg/mL solution, dilute in 50 mL NS to a final concentration 1.85 to 5.6 mg/mL and infuse over 10 minutes.<sup>[7]</sup></div><div class="graphic_reference">References:
<ol>
<li>Flinn IW, et al. Blood 2014; 123:2944.</li>
<li>Rummel MJ, et al. Lancet 2013; 381:1203.</li>
<li>Sehn LH, et al. Blood 2007; 109:4171.</li>
<li>Rituximab injection. United States Prescribing Information. US National Library of Medicine. (Available online at www.dailymed.nlm.nih.gov, accessed on December 1, 2016).</li>
<li>Treanda (bendamustine hydrochloride) injection, concentrate. United States Prescribing Information. US National Library of Medicine. (Available online at www.dailymed.nlm.nih.gov, accessed on December 1, 2016).</li>
<li>Treanda (bendamustine hydrochloride) injection powder, lyophilized, for solution. United States Prescribing Information. US National Library of Medicine. (Available online at www.dailymed.nlm.nih.gov, accessed on December 1, 2016).</li>
<li>Bendeka (bendamustine hydrochloride) injection solution, concentrate. United States Prescribing Information. US National Library of Medicine. (Available online at www.dailymed.nlm.nih.gov, accessed on December 1, 2016).</li>
<li>Rituximab and hyaluronidase human injection for subcutaneous use. United States Prescribing Information. US National Library of Medicine. (Available online at www.dailymed.nlm.nih.gov, accessed on June 30, 2017).</li>
<li>Hiddemann W, Barbui AM, Canales MA, et al. Immunochemotherapy With Obinutuzumab or Rituximab for Previously Untreated Follicular Lymphoma in the GALLIUM Study: Influence of Chemotherapy on Efficacy and Safety. J Clin Oncol 2018; :JCO2017768960.</li>
</ol></div><div id="graphicVersion">Graphic 111141 Version 9.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
